Clever Culture Systems (CC5) Q2 2025 earnings summary

Executive summary

• Finished 2024 ahead of expectations, achieving cashflow break-even for operating activities in the December 2024 quarter, driven by strong sales growth to major pharmaceutical customers including AstraZeneca and Bristol-Myers Squibb.

• APAS technology gained traction with major pharma clients, with AstraZeneca validating and rolling out the technology and Bristol-Myers Squibb placing initial orders.

• Recurring revenue base strengthened by transferring service and maintenance from Thermo Fisher, adding approximately AUD 400,000 in annual recurring revenue.

• Company name changed to Clever Culture Systems Ltd, unifying branding for customers and investors.

• Focus remains on balancing revenue growth with cost control to achieve sustainable profitability.

Financial highlights

• Net cash outflows for the December 2024 quarter were AUD 0.8 million, with break-even cash flows from operating and investing activities.

• Customer receipts and R&D tax incentive each contributed AUD 1 million in cash inflows.

• Cash balance at quarter end was AUD 1.7 million, with AUD 2.3 million in receivables.

• Expectation of break-even or better net operating and investing cash flows for the next two quarters, supported by over AUD 3.9 million in committed cash inflows.

• Gross margin per APAS instrument is approximately 71%, with a sale price of AUD 350,000 and cost of goods around AUD 100,000.

Outlook and guidance

• Anticipates continued break-even or better cash flows for the remainder of FY25, with further instrument placements expected with key pharmaceutical customers over the next 12 months.

• Enhanced sales and marketing program to accelerate expansion into major pharmaceutical customers in 2025.

• No current plans for capital raising or share buybacks; operational cash needs are covered.